Symbols / BCYC
BCYC Chart
About
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 373.20M |
| Enterprise Value | -269.38M | Income | -250.66M | Sales | 28.34M |
| Book/sh | 8.92 | Cash/sh | 9.35 | Dividend Yield | — |
| Payout | 0.00% | Employees | 305 | IPO | — |
| P/E | — | Forward P/E | -1.43 | PEG | — |
| P/S | 13.17 | P/B | 0.60 | P/C | — |
| EV/EBITDA | 0.95 | EV/Sales | -9.51 | Quick Ratio | 10.33 |
| Current Ratio | 10.66 | Debt/Eq | 0.93 | LT Debt/Eq | — |
| EPS (ttm) | -3.62 | EPS next Y | -3.76 | EPS Growth | — |
| Revenue Growth | 3.38% | Earnings | 2026-03-10 | ROA | -20.59% |
| ROE | -34.59% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -5.59% | Profit Margin | 0.00% | Shs Outstand | 49.93M |
| Shs Float | — | Short Float | 5.55% | Short Ratio | 5.82 |
| Short Interest | — | 52W High | 10.84 | 52W Low | 5.03 |
| Beta | 1.61 | Avg Volume | 324.65K | Volume | 664.45K |
| Target Price | $18.80 | Recom | Buy | Prev Close | $5.20 |
| Price | $5.38 | Change | 3.46% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$18.80
Mean price target
2. Current target
$5.38
Latest analyst target
3. DCF / Fair value
$-50.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.38
Low
$6.00
High
$44.00
Mean
$18.80
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-24 | init | Truist Securities | — → Hold | $10 |
| 2025-10-31 | main | Citizens | Market Outperform → Market Outperform | $12 |
| 2025-10-31 | down | RBC Capital | Outperform → Sector Perform | $11 |
| 2025-08-12 | main | JMP Securities | Market Outperform → Market Outperform | $10 |
| 2025-08-12 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $13 |
| 2025-08-11 | main | Oppenheimer | Outperform → Outperform | $44 |
| 2025-07-17 | main | RBC Capital | Outperform → Outperform | $25 |
| 2025-05-06 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $17 |
| 2025-05-02 | main | RBC Capital | Outperform → Outperform | $32 |
| 2025-05-02 | main | B. Riley Securities | Neutral → Neutral | $14 |
| 2025-05-02 | main | JMP Securities | Market Outperform → Market Outperform | $22 |
| 2025-05-02 | reit | Needham | Buy → Buy | $29 |
| 2025-05-01 | main | Barclays | Overweight → Overweight | $15 |
| 2025-04-29 | main | Needham | Buy → Buy | $29 |
| 2025-04-09 | reit | Needham | Buy → Buy | $30 |
| 2025-03-11 | reit | Needham | Buy → Buy | $30 |
| 2025-02-26 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $26 |
| 2025-02-26 | reit | HC Wainwright & Co. | Buy → Buy | $33 |
| 2025-02-26 | reit | Needham | Buy → Buy | $30 |
| 2025-01-22 | reit | Stephens & Co. | Equal-Weight → Equal-Weight | $15 |
- Behavioral Patterns of BCYC and Institutional Flows - Stock Traders Daily Fri, 06 Mar 2026 12
- Bicycle Therapeutics plc (NASDAQ:BCYC) has caught the attention of institutional investors who hold a sizeable 45% stake - Yahoo Finance Fri, 12 Sep 2025 07
- Bicycle Therapeutics reshapes leadership for oncology push to 2028 - Stock Titan ue, 03 Feb 2026 08
- Bicycle Therapeutics: Looking For Their Niche, Addressing Cash Burn (NASDAQ:BCYC) - Seeking Alpha Wed, 15 Oct 2025 07
- Investment Recap: What’s the beta of BCYC stock - Market Rally & Technical Confirmation Trade Alerts - baoquankhu1.vn Sun, 08 Mar 2026 23
- Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat Sat, 14 Feb 2026 08
- Analysts Have Lowered Expectations For Bicycle Therapeutics plc (NASDAQ:BCYC) After Its Latest Results - simplywall.st Wed, 13 Aug 2025 07
- Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com Wed, 13 Aug 2025 07
- Bicycle (BCYC) Q2 Revenue Falls 69% - Nasdaq Fri, 08 Aug 2025 07
- (BCYC) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily Mon, 23 Feb 2026 11
- Bicycle Therapeutics (NASDAQ: BCYC) builds 212Pb radiopharma supply chain - Stock Titan ue, 16 Dec 2025 08
- Analysts Positive on Bicycle Therapeutics (BCYC) After Q2 Results - Yahoo Finance Sun, 07 Sep 2025 07
- Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.6% - Time to Sell? - MarketBeat ue, 10 Feb 2026 08
- Don't Ignore The Insider Selling In Bicycle Therapeutics - simplywall.st Sat, 10 Jan 2026 08
- Oppenheimer reiterates Outperform rating on Bicycle Therapeutics stock - Investing.com ue, 20 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 38000 | — | — | Stock Award(Grant) at price 0.00 per share. | BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2026-01-02 00:00:00 | I |
| 1 | 3032 | — | — | Stock Award(Grant) at price 0.00 per share. | HOPPENOT HERVE | Director | — | 2026-01-02 00:00:00 | D |
| 2 | 723 | 6076.0 | — | Sale at price 8.40 - 8.41 per share. | HANNAY MICHAEL CHARLES FERGUSON | Officer | — | 2025-10-03 00:00:00 | D |
| 3 | 482 | 4103.0 | — | Sale at price 8.40 - 8.60 per share. | YOUNG ALETHIA R. | Chief Financial Officer | — | 2025-10-02 00:00:00 | D |
| 4 | 102 | 872.0 | — | Sale at price 8.55 per share. | SWANTON ROBERT CHARLES | Director | — | 2025-10-02 00:00:00 | D |
| 5 | 5669 | 43612.0 | — | Sale at price 7.48 - 8.02 per share. | LEE KEVIN | Chief Executive Officer | — | 2025-04-03 00:00:00 | D |
| 6 | 2171 | 16851.0 | — | Sale at price 7.48 - 8.02 per share. | MILNES ALISTAIR | Chief Operating Officer | — | 2025-04-03 00:00:00 | D |
| 7 | 733 | 5735.0 | — | Sale at price 7.48 - 8.02 per share. | HANNAY MICHAEL CHARLES FERGUSON | Officer | — | 2025-04-03 00:00:00 | D |
| 8 | 215 | 1724.0 | — | Sale at price 8.02 per share. | YOUNG ALETHIA R. | Chief Financial Officer | — | 2025-04-02 00:00:00 | D |
| 9 | 4595 | 67293.0 | — | Sale at price 14.09 - 15.00 per share. | THOMPSON TRAVIS ALVIN | Officer | — | 2025-01-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -45.17K | -112.86K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.03 | 0.19 | 0.01 | 0.02 |
| NormalizedEBITDA | -163.22M | -168.80M | -107.21M | -64.09M |
| TotalUnusualItems | -1.67M | -594.00K | 0.00 | 358.00K |
| TotalUnusualItemsExcludingGoodwill | -1.67M | -594.00K | 0.00 | 358.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -169.03M | -180.66M | -112.72M | -66.82M |
| ReconciledDepreciation | 7.17M | 6.55M | 3.69M | 1.41M |
| EBITDA | -164.89M | -169.40M | -107.21M | -64.09M |
| EBIT | -172.07M | -175.94M | -110.90M | -65.50M |
| NetInterestIncome | 32.55M | 10.74M | 2.41M | -2.86M |
| InterestExpense | 1.73M | 3.26M | 3.34M | 2.98M |
| InterestIncome | 34.28M | 14.00M | 5.76M | 120.00K |
| NormalizedIncome | -167.40M | -180.18M | -112.72M | -66.82M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -169.03M | -180.66M | -112.72M | -66.82M |
| TotalExpenses | 244.43M | 216.33M | 131.12M | 77.31M |
| TotalOperatingIncomeAsReported | -209.87M | -189.95M | -116.65M | -65.62M |
| DilutedAverageShares | 58.21M | 35.59M | 29.66M | 25.06M |
| BasicAverageShares | 58.21M | 35.59M | 29.66M | 25.06M |
| DilutedEPS | -2.90 | -5.08 | -3.80 | -2.67 |
| BasicEPS | -2.90 | -5.08 | -3.80 | -2.67 |
| DilutedNIAvailtoComStockholders | -169.03M | -180.66M | -112.72M | -66.82M |
| NetIncomeCommonStockholders | -169.03M | -180.66M | -112.72M | -66.82M |
| NetIncome | -169.03M | -180.66M | -112.72M | -66.82M |
| NetIncomeIncludingNoncontrollingInterests | -169.03M | -180.66M | -112.72M | -66.82M |
| NetIncomeContinuousOperations | -169.03M | -180.66M | -112.72M | -66.82M |
| TaxProvision | -4.76M | 1.46M | -1.52M | -1.66M |
| PretaxIncome | -173.80M | -179.21M | -114.24M | -68.48M |
| OtherIncomeExpense | 2.80M | -594.00K | -555.00K | 358.00K |
| OtherNonOperatingIncomeExpenses | 4.48M | |||
| SpecialIncomeCharges | -954.00K | 0.00 | 0.00 | |
| OtherSpecialCharges | 954.00K | |||
| GainOnSaleOfSecurity | -719.00K | -594.00K | -555.00K | 358.00K |
| NetNonOperatingInterestIncomeExpense | 32.55M | 10.74M | 2.41M | -2.86M |
| InterestExpenseNonOperating | 1.73M | 3.26M | 3.34M | 2.98M |
| InterestIncomeNonOperating | 34.28M | 14.00M | 5.76M | 120.00K |
| OperatingIncome | -209.15M | -189.35M | -116.65M | -65.62M |
| OperatingExpense | 244.43M | 216.33M | 131.12M | 77.31M |
| ResearchAndDevelopment | 172.97M | 156.50M | 81.61M | 44.88M |
| SellingGeneralAndAdministration | 71.46M | 59.83M | 49.51M | 32.44M |
| GeneralAndAdministrativeExpense | 71.46M | 59.83M | 49.51M | 32.44M |
| OtherGandA | 29.30M | 23.95M | 49.51M | 32.44M |
| SalariesAndWages | 42.16M | 35.88M | 30.33M | 16.89M |
| TotalRevenue | 35.27M | 26.98M | 14.46M | 11.70M |
| OperatingRevenue | 35.27M | 26.98M | 14.46M | 11.70M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 69.06M | 42.43M | 29.87M | 29.58M |
| ShareIssued | 69.06M | 42.43M | 29.87M | 29.58M |
| TotalDebt | 9.49M | 44.96M | 44.33M | 44.34M |
| TangibleBookValue | 793.06M | 370.93M | 270.78M | 346.25M |
| InvestedCapital | 793.06M | 401.63M | 301.10M | 376.13M |
| WorkingCapital | 861.38M | 492.33M | 316.04M | 422.32M |
| NetTangibleAssets | 793.06M | 370.93M | 270.78M | 346.25M |
| CapitalLeaseObligations | 9.49M | 14.26M | 14.01M | 14.46M |
| CommonStockEquity | 793.06M | 370.93M | 270.78M | 346.25M |
| TotalCapitalization | 793.06M | 401.63M | 301.10M | 376.13M |
| TotalEquityGrossMinorityInterest | 793.06M | 370.93M | 270.78M | 346.25M |
| StockholdersEquity | 793.06M | 370.93M | 270.78M | 346.25M |
| GainsLossesNotAffectingRetainedEarnings | 119.00K | -1.30M | 387.00K | -3.39M |
| OtherEquityAdjustments | 119.00K | -1.30M | 387.00K | -3.39M |
| RetainedEarnings | -680.79M | -511.76M | -331.10M | -218.38M |
| AdditionalPaidInCapital | 1.47B | 883.45M | 601.11M | 567.64M |
| CapitalStock | 890.00K | 550.00K | 387.00K | 384.00K |
| CommonStock | 890.00K | 550.00K | 387.00K | 384.00K |
| TotalLiabilitiesNetMinorityInterest | 163.81M | 224.41M | 139.83M | 133.54M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 96.58M | 154.88M | 86.48M | 97.30M |
| OtherNonCurrentLiabilities | 1.12M | 4.58M | 3.83M | 3.28M |
| NonCurrentDeferredLiabilities | 91.47M | 110.22M | 41.45M | 52.07M |
| NonCurrentDeferredRevenue | 91.47M | 110.22M | 41.45M | 52.07M |
| LongTermDebtAndCapitalLeaseObligation | 3.99M | 40.08M | 41.20M | 41.95M |
| LongTermCapitalLeaseObligation | 3.99M | 9.38M | 10.88M | 12.08M |
| LongTermDebt | 30.70M | 30.32M | 29.87M | |
| CurrentLiabilities | 67.23M | 69.54M | 53.34M | 36.24M |
| OtherCurrentLiabilities | 297.00K | 257.00K | 1.47M | 570.00K |
| CurrentDeferredLiabilities | 10.19M | 24.98M | 20.42M | 19.27M |
| CurrentDeferredRevenue | 10.19M | 24.98M | 20.42M | 19.27M |
| CurrentDebtAndCapitalLeaseObligation | 5.50M | 4.88M | 3.12M | 2.38M |
| CurrentCapitalLeaseObligation | 5.50M | 4.88M | 3.12M | 2.38M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 16.27M | 13.39M | 9.93M | 6.43M |
| PayablesAndAccruedExpenses | 34.97M | 26.03M | 18.40M | 7.58M |
| CurrentAccruedExpenses | 19.17M | 12.98M | 11.93M | 4.86M |
| Payables | 15.79M | 13.05M | 6.47M | 2.72M |
| AccountsPayable | 15.79M | 13.05M | 6.47M | 2.72M |
| TotalAssets | 956.87M | 595.34M | 410.61M | 479.79M |
| TotalNonCurrentAssets | 28.26M | 33.48M | 41.23M | 21.24M |
| OtherNonCurrentAssets | 11.07M | 5.79M | 8.46M | 3.45M |
| NetPPE | 17.19M | 27.68M | 32.77M | 17.79M |
| AccumulatedDepreciation | -18.95M | -13.39M | -7.86M | -4.80M |
| GrossPPE | 36.14M | 41.08M | 40.63M | 22.59M |
| Leases | 10.90M | 11.00M | 10.74M | 809.00K |
| OtherProperties | 23.36M | 28.72M | 28.53M | 21.41M |
| MachineryFurnitureEquipment | 1.87M | 1.35M | 1.36M | 368.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 928.61M | 561.87M | 369.38M | 458.56M |
| OtherCurrentAssets | 13.43M | 11.41M | 9.02M | 7.96M |
| PrepaidAssets | 7.96M | |||
| Receivables | 35.65M | 24.04M | 21.21M | 11.91M |
| OtherReceivables | 35.65M | 24.04M | 19.16M | 10.91M |
| AccountsReceivable | 0.00 | 2.04M | 1.00M | |
| CashCashEquivalentsAndShortTermInvestments | 879.52M | 526.42M | 339.15M | 438.68M |
| CashAndCashEquivalents | 879.52M | 526.42M | 339.15M | 438.68M |
| CashFinancial | 438.68M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -165.96M | -63.56M | -105.10M | -16.82M |
| RepaymentOfDebt | -31.91M | 0.00 | 0.00 | |
| IssuanceOfDebt | 0.00 | 0.00 | 15.00M | |
| IssuanceOfCapitalStock | 544.13M | 249.34M | 5.70M | 298.54M |
| CapitalExpenditure | -1.24M | -2.93M | -18.99M | -2.03M |
| InterestPaidSupplementalData | 1.40M | 2.75M | 2.79M | 2.52M |
| IncomeTaxPaidSupplementalData | 792.00K | 562.00K | 2.23M | 73.00K |
| EndCashPosition | 880.07M | 526.97M | 339.15M | 438.68M |
| BeginningCashPosition | 526.97M | 339.15M | 438.68M | 135.99M |
| EffectOfExchangeRateChanges | -694.00K | 1.35M | -1.12M | -1.21M |
| ChangesInCash | 353.79M | 186.47M | -98.41M | 303.90M |
| FinancingCashFlow | 519.75M | 250.03M | 6.69M | 320.73M |
| CashFlowFromContinuingFinancingActivities | 519.75M | 250.03M | 6.69M | 320.73M |
| ProceedsFromStockOptionExercised | 7.53M | 682.00K | 989.00K | 7.18M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 544.13M | 249.34M | 5.70M | 298.54M |
| CommonStockIssuance | 544.13M | 249.34M | 5.70M | 298.54M |
| NetIssuancePaymentsOfDebt | -31.91M | 0.00 | 0.00 | 15.00M |
| NetLongTermDebtIssuance | -31.91M | 0.00 | 0.00 | 15.00M |
| LongTermDebtPayments | -31.91M | 0.00 | 0.00 | |
| LongTermDebtIssuance | 0.00 | 0.00 | 15.00M | |
| InvestingCashFlow | -1.24M | -2.93M | -18.99M | -2.03M |
| CashFlowFromContinuingInvestingActivities | -1.24M | -2.93M | -18.99M | -2.03M |
| NetPPEPurchaseAndSale | -1.24M | -2.93M | -18.99M | -2.03M |
| PurchaseOfPPE | -1.24M | -2.93M | -18.99M | -2.03M |
| OperatingCashFlow | -164.72M | -60.63M | -86.11M | -14.79M |
| CashFlowFromContinuingOperatingActivities | -164.72M | -60.63M | -86.11M | -14.79M |
| ChangeInWorkingCapital | -33.45M | 76.66M | 672.00K | 39.73M |
| ChangeInOtherWorkingCapital | -31.95M | 68.95M | -2.13M | 37.12M |
| ChangeInOtherCurrentLiabilities | -4.70M | -3.60M | -1.45M | 128.00K |
| ChangeInOtherCurrentAssets | 4.40M | 4.19M | 2.70M | 404.00K |
| ChangeInPayablesAndAccruedExpense | 12.79M | 10.40M | 14.92M | 2.38M |
| ChangeInAccruedExpense | 9.70M | 2.40M | 12.36M | 1.19M |
| ChangeInPayable | 3.10M | 8.00M | 2.56M | 1.20M |
| ChangeInAccountPayable | 3.10M | 8.00M | 2.56M | 1.20M |
| ChangeInPrepaidAssets | -2.04M | -2.07M | -2.02M | -2.97M |
| ChangeInReceivables | -11.95M | -1.20M | -11.35M | 2.68M |
| ChangesInAccountReceivables | 0.00 | 2.48M | -1.64M | 4.54M |
| OtherNonCashItems | -3.23M | 1.04M | 442.00K | 468.00K |
| StockBasedCompensation | 38.08M | 32.48M | 26.78M | 12.08M |
| DeferredTax | -5.23M | 3.31M | -4.98M | -1.67M |
| DeferredIncomeTax | -5.23M | 3.31M | -4.98M | -1.67M |
| DepreciationAmortizationDepletion | 7.17M | 6.55M | 3.69M | 1.41M |
| DepreciationAndAmortization | 7.17M | 6.55M | 3.69M | 1.41M |
| OperatingGainsLosses | 954.00K | |||
| NetIncomeFromContinuingOperations | -169.03M | -180.66M | -112.72M | -66.82M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BCYC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|